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Aim To investigate whether increased YKL-40 levels pos-
itively correlate with graft-vs-host disease (cGVHD) activ-
ity and severity and if YKL-40 could serve as a disease bio-
marker.
Methods This case-control study was conducted at the 
University Hospital Centre Zagreb from July 2013 to Oc-
tober 2015. 56 patients treated with hematopoietic stem 
cell transplantation (HSCT) were included: 35 patients with 
cGVHD and 21 without cGVHD. There was no difference 
between groups in age, sex, median time from transplant 
to study enrollment, intensity of conditioning, type of do-
nor, or source of stem cells. Blood samples were collected 
at study enrollment and YKL-40 levels were measured with 
ELISA. Disease activity was estimated using Clinician’s Im-
pression of Activity and Intensity of Immunosuppression 
scales and disease severity using Global National Institutes 
of Health (NIH) score.
Results YKL-40 levels were significantly higher in cGVHD 
patients than in controls (P = 0.003). The difference re-
mained significant when patients with myelofibrosis were 
excluded from the analysis (P = 0.017). YKL-40 level signifi-
cantly positively correlated with disease severity (P < 0.001; 
correlation coefficient 0.455), and activity estimated using 
Clinician’s Impression of Activity (P = 0.016; correlation co-
efficient 0.412) but not using Intensity of Immunosuppres-
sion (P = 0.085; correlation coefficient 0.296).
Conclusion YKL-40 could be considered a biomarker of 
cGVHD severity and activity. However, validation in a larg-
er group of patients is warranted, as well as longitudinal 
testing of YKL-40 levels in patients at risk of developing 
cGVHD.
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Chronic graft vs host disease (cGVHD) remains the most 
important cause of non-relapse morbidity and mortal-
ity in long-term survivors after hematopoietic stem cell 
transplantation (HSCT) (1,2) and by far its most intriguing 
complication. Although the precise immunologic mecha-
nism leading to cGVHD development still remains to be 
elucidated, there have been some recent advances in un-
derstanding the disease process and identification of po-
tential biomarkers (1-4). cGVHD is a multisystem disorder 
characterized by immune-dysregulation, resulting in im-
paired organ function, increased risk of infections, and de-
teriorated quality of life. Patients present with a variety of 
symptoms and organs involved including the skin, mouth, 
eye, gut, liver, lungs, joints, and genitourinary system (5-7). 
In the recent years the incidence of cGVHD has been in-
creasing (2), likely related to the increased donor (8) and 
recipient age (9), decreased early post-transplant mortal-
ity, use of matched unrelated donors, and peripheral blood 
stem cell grafts (10,11). Identifying biomarkers that could 
be used to predict response to treatment, assess disease 
activity, or distinguish reversible disease activity from irre-
versible damage would be of great clinical value (12). Un-
fortunately, even though a number of potential biomark-
ers have been identified, such as anti-double-strand DNA 
antibodies, adiponectin, soluble IL-2 receptor α (IL-2Rα), 
B-cell activating factor (BAFF), CXCL9, and CD13 (12-15), 
there is still no reliable marker that could be widely used 
in cGVHD patients.
Chitin, a polymer of N-acetylglucosamine, is present in 
coatings and cell walls of many organisms including bacte-
ria, fungi, nematodes, insects, and plants (16-21). Chitinas-
es, whose function is to degrade chitin, have been gener-
ally considered not to be present in mammals due to the 
absence of chitin. YKL-40, a member of the mammalian 
chitinase-like glycoproteins, is a heparin- and chitin-bind-
ing lectin without chitinase activity (22). It is expressed in 
various cell types including neutrophils (23), macrophages 
(24), bone marrow megakariocytes (25), chondrocytes and 
synovial cells (26,27), as well as in malignant cells (28). In 
normal bone marrow, YKL-40 protein is stored in the gran-
ules of the myelocytes and metamyelocytes, and released 
from fully activated cells (29). YKL-40 is also expressed by 
macrophages in vitro during the late stage of differentiation 
(29), in vivo during inflammation (30), and by peritumoral 
macrophages (31). Furthermore, YKL-40 modulates vascular 
endothelial cell morphology by promoting the formation 
of branching tubules, acts as a chemoattractant for en-
dothelial cells, stimulates their migration, and promotes 
the migration and adhesion of vascular smooth mus-
cle cells, indicating its role in angiogenesis (32). It has been 
shown to increase the growth rates of fibroblasts synergisti-
cally working with insulin-like growth factor-1 (IGF-1) (26). 
Its production is regulated by various cytokines. Studies in 
interleukin 6 (IL-6) knockout mice revealed that YKL-40 ex-
pression depended on IL-6 (33). Expression of YKL-40 mRNA 
in human monocyte is strongly stimulated by IFNγ, and in-
hibited by IL-4 and dexamethasone (34).
The physiological and biological functions of YKL-40 are 
still unclear. YKL-40 has been implicated in various inflam-
matory conditions, such as infections (35), autoimmune 
diseases (36-38), liver diseases (39,40) and malignant dis-
eases (24,25,28,41-45). Mainly due to its role in inflamma-
tion (30) and extracellular matrix remodeling (26), it has 
been investigated as a potential biomarker of several au-
toimmune conditions (36,38), as well as those that include 
fibroblast activation (40,43).
In the non-myeloablative allogeneic HSCT setting, high-
er pretransplant recipient and donor plasma YKL-40 con-
centrations suggest a role for YKL-40 as a biomarker for 
relapse and treatment-related toxicity. Recipients with pre-
transplant YKL-40 concentrations above the age-adjusted 
95th percentile (high) had higher relapse-related mortality 
and lower progression-free and overall survival. Recipients 
transplanted with donors with high YKL-40 concentrations 
had an increased probability and risk of grade 2-4 acute 
graft-vs-host disease (aGVHD) (45,46). However, none of the 
studies so far has examined whether post-transplant levels 
of YKL-40 influence the transplant outcomes or GVHD.
Based on the strong involvement of YKL-40 in inflamma-
tory processes and autoimmune disorders, particularly giv-
en that YKL-40 production depends on IL-6 secretion and 
also IFNγ stimulation, we hypothesized that its expression 
was higher in patients with cGVHD than in transplanted 
patients without cGVHD and that it positively correlated 
with disease severity and activity.
PatIeNtS aND MethoDS
Patients
This case-control study is part of a larger project entitled 
“Clinical and Biological Factors Determining Severity and 
Activity of Chronic GVHD After Allogeneic Hematopoietic 
Stem Cell Transplantation” at the University Hospital Cen-
ter Zagreb. The project included all patients who were re-
ferred to hematologist for post-transplantation follow up, 
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regardless of their age or underlying diagnosis, who con-
sented to the study participation. Excluded from participa-
tion were patients with significant medical condition or 
any other significant circumstance that could affect the 
patient’s ability to tolerate, comply, or complete the study 
and patients who according to the investigators assess-
ment had life expectancy less than 3 months. Over the 
period of July 2013 to October 2015, 76 patients treated 
with hematopoietic stem cell transplantation (HCST) were 
included in the project: 47 patients who developed cGVHD 
and 29 who did not develop cGVHD and who served as 
controls (Table 1).
For 56 patients (35 patients with cGVHD and 21 controls) 
included in the project serum samples were obtained at 
enrolment and stored. These patients were included in 
the study presented here. Prior to enrolment all partici-
pants signed the informed consent, and the study was 
approved by the University Hospital Center Zagreb Ethics 
Committee.
Data collection
Data regarding the diagnosis, time and type of transplant, 
and donor characteristics, and demographic data were col-
lected. Blood samples for measurement of YKL-40 level and 
C-reactive protein (CRP) were taken at the time of study 
enrollment. For patients with established cGVHD diagnosis 
additional data regarding the severity and activity of dis-
ease were collected using predefined forms. Disease ac-
tivity was defined by Clinician’s Impression of Activity and 
Intensity of Immunosuppression Scale. Clinician’s impres-
sion of activity was defined as: inactive, off systemic ther-
apy or topical immunosuppression; inactive, on systemic 
therapy or topical immunosuppression; active irrespective 
of the level of current therapy; and highly active irrespec-
tive of the level of current therapy (47). Intensity of immu-
nosuppression scale was defined as: none; mild = single 
agent prednisone <0.5 mg/kg/d; moderate = prednisone 
≥0.5 mg/kg/d and/or any single agent/modality; high = 2 
or more agents/modalities ± prednisone ≥0.5 mg/kg/d 
(47,48). Disease severity was defined by Global National In-
stitutes of health (NIH) scoring. Patients had mild cGVHD 
if only 1 or 2 organs (except lungs) were involved, with a 
maximum score 1 in all affected organs. Patients had mod-
erate cGVHD if at least 1 organ was involved with clinically 
significant, but not major disability (maximum score 2) or 
3 or more organs with no clinically significant functional 
impairment (maximum score 1 in all affect organs); a lung 
score 1 was classified as moderate. Patients had severe 
cGVHD if they had major impairment caused by cGVHD 
(score 3 in any organ); lung scores of 2 or 3 were classified 
as severe. Organs scored included the skin, eyes, mouth, 
gastrointestinal tract, liver, lungs, and joint/fascia. The geni-
tal area was scored only in women (49).
YKL-40 analysis
Plasma samples were prepared from EDTA (EDTA)-antico-
agulated blood taken at the time of inclusion and were 
tabLe 1. Characteristics of patients who underwent hematopoietic stem cell transplantation (hSCt) with and without chronic graft-
vs-host disease (cGVhD)
cGVhD (n = 35) Control (n = 21) P
Median age, years (range)  45 (9-60)  40 (16-59) 0.912
Sex female, n (%)  18 (51.4)  10 (47.6) 0.783
male, n (%)  17 (48.6)  11 (52.4)
Diagnosis aplastic anemia, n (%)   3 (8.6)   1 (4.8) 0.679
acute lymphoblastic leukemia, acute myeloid leukemia, n (%)  21 (60.0)  10 (47.6)
chronic lymphocytic leukemia, n (%)   1 (2.9)   2 (9.5)
chronic myeloid leukemia and myeloproliferative diseases, n (%)   6 (17.1)   6 (28.6)
lymphoma, n (%)   2 (5.7)   2 (9.5)
immunodeficiencies, n (%)   1 (2.9)   0 (0.0)
multiple myeloma, n (%)   1 (2.9)   0 (0.0)
Donor relationship related, n (%)  21 (60.0)   9 (42.9) 0.213
unrelated, n (%)  14 (40.0)  12 (57.1)
Cell source bone marrow, n (%)  15 (42.9)   8 (38.1) 0.726
peripheral cells, n (%)  20 (57.1)  13 (61.9)
Days from transplantation 
to enrollment, median 
(range)
463 (61-7853) 428 (190-1770) 0.441
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stored at -80°C until YKL-40 analysis. YKL-40 plasma con-
centration was measured using a commercially available 
ELISA kit (R&D Systems Europe, Abingdon, UK).
Statistical analysis
After testing for normality using Kolmogorov-Smirnov 
test and due to small sample size we decided to use non-
parametric tests. Categorical variables are presented as 
frequencies and corresponding percentages and quanti-
tative variables as medians and interquartile ranges. The 
differences in categorical clinical parameters between pa-
tients and controls were analyzed using Fisher exact test or 
Fisher-Freeman-Halton exact test of independence when 
the contingency table was larger than 2 × 2, while differ-
ences in quantitative variables were analyzed using Mann-
Whitney U test. Differences in YLK-40 levels between NIH 
groups were analyzed using Kruskal-Wallis test. Spearman 
correlation coefficients were calculated to assess the cor-
relation between YLK-40 levels and other clinical variables. 
P values below 0.05 were considered significant. Data anal-
ysis software system IBM SPSS Statistics, version 21.0 (IBM 
Corp., Armonk, NY, USA) was used.
ReSuLtS
Patient characteristics
Median age was 45 years (interquartile range 27-52 years) 
in the cGVHD group and 40 years (interquartile range 33-
54 years) in the control group. There were 18 women in 
cGVHD group and 9 in the control group. Graft stem cell 
source was the bone marrow in 15 (42.9%) and 8 (38.1%) 
and peripheral blood cells in 20 (57.1%) and 13 (61.9%) pa-
tients in cGVHD and control group, respectively. 17 (48.6%) 
and 8 (38.1%) patients received transplant from a related 
donor, while 18 (51.4%) and 13 (61.9%) patients received it 
from an unrelated donor in cGVHD and control group, re-
spectively (Table 1). Myeloablative conditioning was used 
in 17 (48.6%) and 8 (38.1%) patients in cGVHD and control 
group, respectively. In the cGVHD group, 4 patients had 
mild, 15 moderate, and 16 severe symptoms as assessed 
by Global NIH score.
CGVHD and control patient groups were comparable ac-
cording to age, sex, time from transplantation to enroll-
ment, type of disease, cell source, donor relationship, 
intensity of conditioning, total body irradiation use in con-
ditioning, and myelofibrosis as primary disease (Table 1).
Plasma YKL-40 concentration in cGVhD and control 
group
YKL-40 levels in cGVHD patients were significantly high-
er than in the control group (median 707 pg/mL [inter-
quartile range 525-1054] vs 314 pg/mL [interquartile range 
169-635]; P = 0.003) (Figure 1A). Since YKL-40 is known to 
be increased in patients suffering from myelofibrosis, we 
excluded the data of all the patients with a history of my-
elofibrosis from the analysis (3 patients, [8.6%] in cGVHD 
FIGuRe 1. (A) Significantly higher YKL-40 serum concentration in chronic graft-vs-host disease (cGVhD) patients compared to control 
group. (B) the difference in YKL-40 serum concentration between cGVhD and control group remained significant after patients suf-
fering from myelofibrosis were excluded from the analysis. 6 patients were excluded, 3 from each group.
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group and 3 patients, [14.3%] in control group). After these 
patients were excluded, the concentration of YKL-40 was 
still significantly higher in cGVHD group than in the control 
group (median 633.5 pg/mL [range 71-1689] vs 351.5 pg/
mL [range 105-2790]; P = 0.017) (Figure 1B).
Correlation of YKL-40 concentration and disease activity 
and severity
YKL-40 levels significantly positively correlated with Clini-
cian’s Impression of Activity (P = 0.016; correlation coef-
ficient 0.412) and Global NIH score (P < 0.001; correlation 
coefficient 0.455) (Figure 2), but not with Intensity of Im-
munosuppression (P = 0.085; correlation coefficient 0.296). 
Since YKL-40 protein is involved in inflammation process, 
we tested its correlation with the CRP level, to establish if 
the YKL-40 level was increased due to persistent chronic 
inflammation not noticed by the examining physician and 
found no significant correlation (P = 0.581) (Table 2).
DISCuSSIoN
Our study shows that the level of circulating YKL-40 is sig-
nificantly higher in patients with cGVHD than in transplant-
ed patients without cGVHD and correlates with disease se-
verity and activity, as measured by Global NIH score and 
Clinicians Impression of Activity, respectively.
Although the exact role of glycoprotein YKL-40 in chronic 
inflammation is still not elucidated, YKL-40 concentration 
was found to be increased in 54% of patients with clinically 
active rheumatoid arthritis (RA). In patients in whom RA be-
came inactive serum YKL-40 concentration decreased after 
12 months, but increased in patients with RA flare (50). Fur-
thermore, it has been shown that the level of circulating 
YKL-40 depends on IL–6 secretion, stimulated by IFNγ (45) 
and inhibited by IL-4 (33,34,51). Also, IL-6 and IFNγ have 
been shown to increase during GVHD development (52) 
and IL-6 is crucial for Th17 pathway (53), while production 
of IL-4 has been shown to be decreased in cGVHD patients 
(54). This could in part explain why YKL-40 is increased in 
active cGVHD reaction.
Furthermore, it was previously shown that patients with 
myelofibrosis had highly elevated levels of circulating YKL-
40 in comparison to healthy controls (43). However, in our 
study the difference in plasma YKL-40 concentration be-
tween cGVHD group and control group remained signifi-
cant after patients with myelofibrosis were excluded. The 
cause of elevated YKL-40 in myelofibrosis patients has not 
been found, but increased bone turnover and pronounced 
chronic inflammation have been implicated (43). Both pro-
cesses are aborted after successful HSCT, and therefore, the 
fact that patient once had myelofibrosis should not influ-
ence the post-transplant level of YKL-40 protein. The effect 
of donor and recipient pre-transplant level of circulating 
YKL-40 on transplant outcomes (ie, relapse-related mor-
tality, progression-free survival, overall survival, and acute 
GVHD incidence) has been reported, but post-transplant 
levels have not been investigated (45,46).
Even though our study distinctly shows concentration of 
YKL-40 to be significantly higher in patients with cGVHD 
in comparison to controls, it has several limitations. It is a 
single center study with a limited number of included pa-
tients. Albeit there was no significant difference between 
groups in time from transplant to sampling, there was a 
considerably wide range among patients within each 
group (range for cGVHD group was 61 to 7853 days, 
control 190 to 1770 days). This is because patients 
FIGuRe 2. YKL-40 serum concentration was positively corre-
lated with global National Institutes of health score.
tabLe 2. univariate analysis of YKL-40 serum concentration 






Clinicians impression of activity 0.412 0.016
Intensity of immunosuppression 0.296 0.085
Global National Institutes of Health score 0.455 <0.001
National Institutes of Health average score 0.208 0.231
C reactive protein 0.097 0.581
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were included at various points after having been diag-
nosed with cGVHD and at various stages of disease. Even 
though it would be preferable if the study included only 
newly diagnosed patients to limit the influence of disease 
advancement and/or therapy, the patients included in this 
study were clinically very well characterized according to 
2005 NIH Consensus criteria.
In our study YKL-40 levels positively correlated with Glob-
al NIH score, a measure of disease severity, and Clinician’s 
Impression of Activity, a measure of disease activity. We 
agree that data shown here do not prove YKL-40 protein 
to be a valid biomarker, but they certainly indicate that it 
is a strong new candidate. In our opinion, YKL-40 needs to 
be explored as a potential biomarker on a larger number of 
cGVHD patients. In addition, a longitudinal study of post-
transplant patients, with serial, predefined time points is 
needed to validate these results, establish the dynamics of 
YKL-40 expression, and determine its role in evaluating the 
response to treatment.
Funding This work was funded by the Unity Through Knowledge Fund proj-
ect entitled “Clinical And Biological Factors Determining Severity and Ac-
tivity of Chronic Graft-Versus-Host Disease After Allogeneic Hematopoietic 
Stem Cell Transplantation“.
ethical approval Received from the University Hospital Centre Zagreb and 
University of Zagreb School of Medicine.
Declaration of authorship ND designed the study, analyzed and interpret-
ed the data, and wrote the manuscript. IK contributed through acquisition 
and analysis of data and drafting the manuscript. ZP contributed through 
data analysis and interpretation. MM contributed through data analysis and 
interpretation. LD contributed through data acquisition and interpretation, 
and drafting the manuscript. DP contributed through data acquisition and 
interpretation, and drafting the manuscript. IP contributed through data 
interpretation and drafting the manuscript. VK contributed through data 
acquisition and drafting the manuscript. RV contributed through concep-
tion and design of the study and drafting the manuscript. SZP contributed 
through data interpretation and drafting the manuscript. DN contributed 
through conception and design of the study and drafting the manuscript. 
All authors revised the work critically for important intellectual content, ap-
proved final version of the manuscript, and agreed to be accountable for all 
aspects of the work.
Competing interests All authors have completed the Unified Competing 
Interest form at www.icmje.org/coi_disclosure.pdf (available on request 
from the corresponding author) and declare: no support from any organi-
zation for the submitted work; no financial relationships with any organiza-
tions that might have an interest in the submitted work in the previous 3 
years; no other relationships or activities that could appear to have influ-
enced the submitted work.
References
1 Socié G, Stone JV, Wingard JR, Weisdorf D, henslee-Downey 
PJ, bredeson C, et al. Long-term survival and late deaths after 
allogeneic bone marrow transplantation. Late effects Working 
Committee of the International bone Marrow transplant Registry. 
N engl J Med. 1999;341:14-21. Medline:10387937 doi:10.1056/
NeJM199907013410103
2 arai S, arora M, Wang t, Spellman SR, he W, Couriel DR, et 
al. Increasing Incidence of chronic graft-versus-host disease 
in allogeneic transplantation: a report from the Center for 
International blood and Marrow transplant Research. biol 
blood Marrow transplant. 2015;21:266-74. Medline:25445023 
doi:10.1016/j.bbmt.2014.10.021
3 Paczesny S, hakim Ft, Pidala J, Cooke KR, Lathrop J, Griffith LM, et 
al. National Institutes of health Consensus Development Project 
on Criteria for Clinical trials in Chronic Graft-versus-host Disease: 
III. the 2014 biomarker Working Group Report. biol blood Marrow 
transplant. 2015;21:780-92. Medline:25644957 doi:10.1016/j.
bbmt.2015.01.003
4 Socié G, Ritz J. Current issues in chronic graft-versus-host disease. 
blood. 2014;124:374-84. Medline:24914139 doi:10.1182/blood-
2014-01-514752
5 atkinson K. Chronic graft-versus-host disease. bone Marrow 
transplant. 1990;5:69-82. Medline:2178709
6 Jagasia Mh, Greinix ht, arora M, Williams KM, Wolff D, Cowen eW. 
National Institutes of health Consensus Development Project on 
Criteria for Clinical trials in Chronic Graft-versus-host Disease: 
I. the 2014 Diagnosis and Staging Working Group report. biol 
blood Marrow transplant. 2015;21:389-401. Medline:25529383 
doi:10.1016/j.bbmt.2014.12.001
7 Jacobshon Da, Montross S, anders V, Vogelsang Gb. Clinical 
importance of confirming or excluding the diagnosis of chronic 
graft-versus-host disease. bone Marrow transplant. 2001;28:1047-
51. Medline:11781615 doi:10.1038/sj.bmt.1703278
8 Kollman C, howe CW, anasetti C, antin Jh, Davies SM, Filipovich 
ah, et al. Donor characteristics as risk factors in recipients after 
transplantation of bone marrow from unrelated donors: the 
effect of donor age. blood. 2001;98:2043-51. Medline:11567988 
doi:10.1182/blood.V98.7.2043
9 arora M, Klein JP, Weisdorf DJ, hassebroek a, Flowers Me, Cutler CS, 
et al. Chronic GVhD risk score: a Center for International blood and 
Marrow transplant Research analysis. blood. 2011;117:6714-20. 
Medline:21493797 doi:10.1182/blood-2010-12-323824
10 Remberger M, beelen DW, Fauser a, basara N, basu o, Ringdén 
o. Increased risk of extensive chronic graft-versus-host disease 
after allogeneic peripheral blood stem cell transplantation using 
unrelated donors. blood. 2005;105:548-51. Medline:15367429 
doi:10.1182/blood-2004-03-1000
11 Ringdén o, Labopin M, bacigalupo a, arcese W, Schaefer uW, 
Willemze R, et al. transplantation of peripheral blood stem cells as 
compared with bone marrow from hLa-identical siblings in adult 
patients with acute myeloid leukemia and acute lymphoblastic 
leukemia. J Clin oncol. 2002;20:4655-64. Medline:12488410 
doi:10.1200/JCo.2002.12.049
12 Schultz KR, Miklos Db, Fowler D, Cooke K, Shizuru J, Zorn e, et al. 
toward biomarkers for chronic graft-versus-host disease: National 
Institutes of health consensus development project on criteria 
245Duraković et al: YKL-40 glycoprotein and chronic GVHD
www.cmj.hr
for clinical trials in chronic graft-versus-host disease: III. biol 
blood Marrow transplant. 2006;12:126-37. Medline:16443511 
doi:10.1016/j.bbmt.2005.11.010
13 Fujii h, Cuvelier G, She K, aslanian S, Shimizu h, Kariminia a, et al. 
biomarkers in newly diagnosed pediatric-extensive chronic graft-
versus-host disease: a report from the Children’s oncology Group. 
blood. 2008;111:3276-85. Medline:17925486 doi:10.1182/blood-
2007-08-106286
14 Nakasone h, binh PN, Yamazaki R, tanaka Y, Sakamoto K, ashizawa 
M, et al. association between serum high-molecular- weight 
adiponectin level and the severity of chronic graft-versus-host 
disease in allogeneic stem cell transplantation recipients. blood. 
2011;117:3469-72. Medline:21258011 doi:10.1182/blood-2010-10-
316109
15 Kitko CL, Levine Je, Storer be, Chai X, Fox Da, braun tM, et al. 
Plasma CXCL9 elevations correlate with chronic GVhD diagnosis. 
blood. 2014;123:786-93. Medline:24363401 doi:10.1182/blood-
2013-08-520072
16 broekaert WF, Van Parijs J, Leyns F, Joos h, Peumans WJ. a chitin- 
binding lectin from stinging nettle rhizomes with antifungal 
properties. Science. 1989;245:1100-2. Medline:17838811 
doi:10.1126/science.245.4922.1100
17 Watanabe t, Suzuki K, oyanagi W, ohnishi K, tanaka h. Gene 
cloning of chitinase a1 from bacillus circulans WL-12 revealed its 
evolutionary relationship to Serratia chitinase and to the type III 
homology units of fibronectin. J biol Chem. 1990;265:15659-65. 
Medline:2203782
18 hayes CK, Klemsdal S, Lorito M, Di Pietro a, Peterbauer C, Nakas 
JP, et al. Isolation and sequencing of an endochitinase-encoding 
gene from a cDNa library of trichoderma harzianum. Gene (amst). 
1994;120:143-8. doi:10.1016/0378-1119(94)90797-8
19 Kramer KJ, Corpuz L, Choi hK, Muthukrishnan S. Sequence of a 
cDNa and expression of the gene encoding epidermal and gut 
chitinases of Manduca sexta. Insect biochem Mol biol. 1993;23:691-
701. Medline:8353525 doi:10.1016/0965-1748(93)90043-R
20 Krishnan a, Nair PN, Jones D. Isolation, cloning, and 
characterization of a new chitinase stored in the active form in 
chitin-lined venom reservoir. J biol Chem. 1994;269:20971-6. 
Medline:8063715
21 Jekel Pa, hartman Jbh, beintema JJ. the primary structure of 
hevamine, an enzyme with lysozyme/chitinase activity from hevea 
brailiensis latex. eur J biochem. 1991;200:123-30. Medline:1879417 
doi:10.1111/j.1432-1033.1991.tb21057.x
22 Rehli M, Krause SW, andreesen R. Molecular characterization of 
the gene for human cartilage gp-39 (ChI3L1), a member of the 
chitinase protein family and marker for late stages of macrophage 
differentiation. Genomics. 1997;43:221-5. Medline:9244440 
doi:10.1006/geno.1997.4778
23 Volck b, Price Pa, Johansen JS, Sorensen o, benfield tL, Nielsen hJ. 
YKL-40, a mammalian member of the chitinase family, is a matrix 
protein of specific granules in human neutrophils. Proc assoc am 
Physicians. 1998;110:351-60. Medline:9686683
24 biggar RJ, Johansen JS, Smedby Ke, Rostgaard K, Chang et, 
adami ho, et al. Serum YKL-40 and interleukin 6 levels in hodgkin 
lymphoma. Clin Cancer Res. 2008;14:6974-8. Medline:18980992 
doi:10.1158/1078-0432.CCR-08-1026
25 Mylin aK, andersen NF, Johansen JS, abildgaard N, heickendorff 
L, Standal t, et al. Serum YKL-40 and bone marrow angiogenesis 
in multiple myeloma. Int J Cancer. 2009;124:1492-4. 
Medline:19089918 doi:10.1002/ijc.24110
26 Recklies aD, White C, Ling h. the chitinase 3-like protein human 
cartilage glycoprotein 39 (hC-gp39) stimulates proliferation of 
human connective tissue cells and activates both extracellular 
signal-regulated kinase - and protein kinase b-mediated signaling 
pathways. biochem J. 2002;365:119-26. Medline:12071845 
doi:10.1042/bj20020075
27 Volck b, ostergaard K. Johansen, Garbarsch C, Price Pa. the 
distribution of YKL-40 in osteoarthritic and normal human articular 
cartilage. Scand J Rheumatol. 1999;28:171-9. Medline:10380840 
doi:10.1080/03009749950154257
28 Johansen JS, Schultz Na, Jensen bV. Plasma YKL-40: a potential 
new cancer biomarker? Future oncol. 2009;5:1065-82. 
Medline:19792974 doi:10.2217/fon.09.66
29 Renkema Gh, boot RG, au FL, Donker-Koopman We, Strijland a, 
Muijsers ao. Chitotriosidase, a chitinase, and the 39-kDa human 
cartilage glycoprotein, a chitin-binding lectin, are homologues of 
family 18 glycosyl hydrolases secreted by human macrophages. 
eur J biochem. 1998;251:504-9. Medline:9492324 doi:10.1046/
j.1432-1327.1998.2510504.x
30 baeten D, boots aMh, Steenbakkers PG, elewaut D, bos e, 
Verheijden GF, et al. human cartilage gp-39+, CD16+ monocytes in 
peripheral blood and synovium. Correlation with joint destruction 
in rheumatoid arthritis. arthritis Rheum. 2000;43:1233-43. 
Medline:10857782 doi:10.1002/1529-0131(200006)43:6<1233::aID-
aNR6>3.0.Co;2-9
31 Junker N, Johansen JS, andersen Cb, Kristjansen Pe. expression 
of YKL-40 by peritumoral macrophages in human small cell 
lung cancer. Lung Cancer. 2005;48:223-31. Medline:15829322 
doi:10.1016/j.lungcan.2004.11.011
32 Nishikawa KC, Millis aJt. gp38k (ChI3L1) is a novel adhesion and 
migration factor for vascular cells. exp Cell Res. 2003;287:79-87. 
Medline:12799184 doi:10.1016/S0014-4827(03)00069-7
33 Kzhyshkowska J, Mamidi S, Gratchev a, Kremmer e, 
Schmuttermaier C, Krusell L, et al. Novel stabilin-1 interacting 
chitinase-like protein (SI-CLP) is up-regulated in alternatively 
activated macrophages and secreted via lysosomal pathway. 
blood. 2006b;107:3221-8. Medline:16357325 doi:10.1182/blood-
2005-07-2843
34 Di Rosa M, Musumeci M, Scuto a, Musumeci S, Malaguarnera L. 
effect of interferon-gamma, interleukin-10, lipopolysaccharide 
GRAFT-VS-HOST DISEASE 246 Croat Med J. 2016;57:239-46
www.cmj.hr
and tumor necrosis factor-alpha on chitotriosidase synthesis 
in human macrophages. Clin Chem Lab Med. 2005;43:499-502. 
Medline:15899671 doi:10.1515/CCLM.2005.088
35 ostergaard C, Johansen JS, benfield t, Price Pa. Lundgren JD. 
YKL-40 is elevated in cerebrospinal fluid from patients with 
purulent meningitis. Clin Diagn Lab Immunol. 2002;9:598-604. 
Medline:11986266
36 Vind I, Johansen JS, Price Pa, Munkholm P. Serum YKL-40, 
a potential new marker of disease activity in patients with 
inflammatory bowel disease. Scand J Gastroenterol. 2003;38:599-
605. Medline:12825867 doi:10.1080/00365520310000537
37 Van bilsen Jh, van Dongen h, Lard LR, van der Voort eI, 
elferink DG, bakker aM, et al. Functional regulatory immune 
responses against human cartilage glycoprotein-39 in health vs. 
proinflammatory responses in rheumatoid arthritis. Proc Natl 
acad Sci u S a. 2004;101:17180-5. Medline:15569925 doi:10.1073/
pnas.0407704101
38 Grosso S, Margollicci Ma, bargagli e, buccoliero QR, Perrone 
a, Galimberti D, et al. Serum levels of chitotriosidase as a 
marker of disease activity and clinical stage in sarcoidosis. 
Scand J Clin Lab Invest. 2004;64:57-62. Medline:15025429 
doi:10.1080/00365510410004092
39 Malaguarnera L, Di Rosa M, Zambito aM, dell’ombra N, Nicoletti 
F, Malaguarnera M. Chitotriosidase gene expression in Kupffer 
cells from patients with non-alcoholic fatty liver disease. Gut. 
2006;55:1313-20. Medline:16825325 doi:10.1136/gut.2005.075697
40 tran a, benzaken S, Saint-Paul MC, Guzman-Granier e, hastier 
P, Pradier C, et al. Chondrex (YKL-40), a potential new serum 
fibrosis marker in patients with alcoholic liver disease. eur J 
Gastroenterol hepatol. 2000;12:989-93. Medline:11007134 
doi:10.1097/00042737-200012090-00004
41 Mylin aK, andersen NF, Johansen JS, abildgaard N, heickendorff 
t, Standal t, et al. Serum YKL-40 and bone marrow angiogenesis 
in multiple myeloma. Int J Cancer. 2009;124:1492-4. 
Medline:19089918 doi:10.1002/ijc.24110
42 bergmann oJ, Johansen JS, Klausen tW, Mylin aK, Kristensen JS, 
Kjeldsen e, et al. high serum concentration of YKL-40 is associated 
with short survival inpatients with acute myeloid leukemia. Clin 
Cancer Res. 2005;11:8644-52. Medline:16361549 doi:10.1158/1078-
0432.CCR-05-1317
43 bjřrn eM, Lykkegaard andersen C, Jensen MK, hasselbalch hC. 
Circulating YKL-40 in myelofibrosis a potential novel biomarker 
of disease activity and the inflammatory state. eur J haematol. 
2014;93:224-8. Medline:24689875 doi:10.1111/ejh.12332
44 andersen CL, bjřrn Me, McMullin MF, harrison C, Samuelsson 
J, ejerblad e, et al. Circulating YKL-40 in patients with essential 
thrombocythemia and polycythemia vera treated with the novel 
histone deacetylase inhibitor vorinostat. Leuk Res. 2014;38:816-21. 
Medline:24836761 doi:10.1016/j.leukres.2014.04.002
45 Morup aM, Kornblit b, Johansen JS, Masmas tN, Madsen ho, 
Vindelov L, et al. the prognostic value of YKL-40 concentrations 
in nonmyeloablative conditioning allogeneic hematopoietic cell 
transplantation. biol blood Marrow transplant. 2011;17:1299-307. 
Medline:21232622 doi:10.1016/j.bbmt.2011.01.008
46 Kornblit b, tang W, Lee S. the prognostic value of YKL-40 in 
allogeneic hematopoietic cell transplantation. blood. 2014;123.
47 Grkovic L, baird K, Steinberg SM, Williams KM, Pulanic D, 
Cowen eW, et al. Clinical laboratory markers of inflammation as 
determinants of chronic graft-versus-host disease activity and 
NIh global severity. Leukemia. 2012;26:633-43. Medline:22005783 
doi:10.1038/leu.2011.254
48 Mitchell Sa, Leidy NK, Mooney Kh, Dudley WN, beck SL, LaStayo 
PC, et al. Determinants of functional performance in long-term 
survivors of allogeneic hematopoietic stem cell transplantation 
with chronic graft-versus-host disease (cGVhD). bone Marrow 
transplant. 2010;45:762-9. Medline:19784078 doi:10.1038/
bmt.2009.238
49 Filipovich ah, Weisdorf D, Pavletic S, Socie G, Wingard JR, Lee SJ, 
et al. National Institutes of health consensus development project 
on criteria for clinical trials in chronic graft-versus-host disease: I. 
Diagnosis and staging working group report. biol blood Marrow 
transplant. 2005;11:945-56. Medline:16338616 doi:10.1016/j.
bbmt.2005.09.004
50 Johansen JS, Stoltenberg M, hansen M, Florescu a, horslec-
Petersen K, Lorenzen I, et al. Serum YKL-40 concentration in 
patients with rheumatoid arthritis: relation to disease activity. 
Rheumatology. 1999;38:618-26. Medline:10461474 doi:10.1093/
rheumatology/38.7.618
51 henden aS, hill GR. Cytokines in graft-versus-host disease. J 
Immunol. 2015;194:4604-12. Medline:25934923 doi:10.4049/
jimmunol.1500117
52 Imamura M, hashino S, Kobayashi h, Kubayashi S, hirano 
S, Minagawa t, et al. Serum cytokine levels in bone marrow 
transplantation: synergistic interaction of interleukin-6, 
interferon-gamma, and tumor necrosis factor-alpha in graft-
versus-host disease. bone Marrow transplant. 1994;13:745-51. 
Medline:7920309
53 Chen X, Das R, Komorowski R, beres a, hessner MJ, Mihara M, et 
al. blockade of interleukin-6 signaling augments regulatory t-cell 
reconstitution and attenuates the severity of graft-versus-host 
disease. blood. 2009;114:891-900. Medline:19491393 doi:10.1182/
blood-2009-01-197178
54 Rozmus J, Schultz KR, Wynne K, Kariminia a, Satyanarayana P, Krailo 
M, et al. early and late extensive chronic graft-versus-host disease 
in children is characterized by different th1/th2 cytokine profiles: 
findings of the Children’s oncology Group Study aSCt0031. biol 
blood Marrow transplant. 2011;17:1804-13. Medline:21669298 
doi:10.1016/j.bbmt.2011.05.011
